Cargando…

Aberrant miRNAs expressed in HER-2 negative breast cancers patient

BACKGROUND: Breast cancer is a highly heterogeneous pathology, exhibiting a number of subtypes commonly associated with a poor outcome. Due to their high stability, microRNAs are often regarded as non-invasive cancer biomarkers, having an expression pattern specific for their ‘cell of origin’. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Braicu, Cornelia, Raduly, Lajos, Morar-Bolba, Gabriela, Cojocneanu, Roxana, Jurj, Ancuta, Pop, Laura-Ancuta, Pileczki, Valentina, Ciocan, Cristina, Moldovan, Alin, Irimie, Alexandru, Eniu, Alexandru, Achimas-Cadariu, Patriciu, Paradiso, Angelo, Berindan-Neagoe, Ioana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196003/
https://www.ncbi.nlm.nih.gov/pubmed/30342533
http://dx.doi.org/10.1186/s13046-018-0920-2
_version_ 1783364494594932736
author Braicu, Cornelia
Raduly, Lajos
Morar-Bolba, Gabriela
Cojocneanu, Roxana
Jurj, Ancuta
Pop, Laura-Ancuta
Pileczki, Valentina
Ciocan, Cristina
Moldovan, Alin
Irimie, Alexandru
Eniu, Alexandru
Achimas-Cadariu, Patriciu
Paradiso, Angelo
Berindan-Neagoe, Ioana
author_facet Braicu, Cornelia
Raduly, Lajos
Morar-Bolba, Gabriela
Cojocneanu, Roxana
Jurj, Ancuta
Pop, Laura-Ancuta
Pileczki, Valentina
Ciocan, Cristina
Moldovan, Alin
Irimie, Alexandru
Eniu, Alexandru
Achimas-Cadariu, Patriciu
Paradiso, Angelo
Berindan-Neagoe, Ioana
author_sort Braicu, Cornelia
collection PubMed
description BACKGROUND: Breast cancer is a highly heterogeneous pathology, exhibiting a number of subtypes commonly associated with a poor outcome. Due to their high stability, microRNAs are often regarded as non-invasive cancer biomarkers, having an expression pattern specific for their ‘cell of origin’. METHOD: Triple negative breast cancer (TNBC: ER-, PR-, Her-2-) and double positive breast cancer (DPBC: ER+, PR+, Her-2) miRNA expression patterns were obtained by analysis of the TCGA (The Cancer Genome Atlas) data, followed by PCR-array analysis on plasma samples from 20 TNBC patients, 14 DPBC patients and 11 controls. RESULTS: Three downregulated and nine upregulated miRNAs were obtained from the TNBC analysis. Five overexpressed miRNAs were identified in the DPBC group. Four of the dysregulated miRNAs (miR-10a, miR-125b, miR-210 and miR-489) were common for both groups. The cluster miR-17-92 (miR-17, miR-20a, miR-20b, and miR-93), along with miR-130, miR-22 and miR-29a/c, were found to differentiate between TNBC and DPBC. A panel of five transcripts (miR-10a, miR-125, miR-193b, miR-200b and miR-489) was validated in a new set of plasma samples. The overlapping of TCGA and plasma profiling data revealed miR-200b, miR-200c, miR-210 and miR-29c as common signature. MiR-200b was validated on additional normal and tumor tissue samples. The expression level of this transcript from the TCGA data was correlated with lung and bone metastatic genes. CONCLUSION: The miR-200b presents a great potential for the future advancements in the diagnostic/prognostic and therapeutic approach of TNBC, along with other coding or non-coding transcripts. However, this needs to be further integrated in a regulatory network that acts in conjunction with other markers that affect the patients’ prognosis or response to therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13046-018-0920-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6196003
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-61960032018-10-30 Aberrant miRNAs expressed in HER-2 negative breast cancers patient Braicu, Cornelia Raduly, Lajos Morar-Bolba, Gabriela Cojocneanu, Roxana Jurj, Ancuta Pop, Laura-Ancuta Pileczki, Valentina Ciocan, Cristina Moldovan, Alin Irimie, Alexandru Eniu, Alexandru Achimas-Cadariu, Patriciu Paradiso, Angelo Berindan-Neagoe, Ioana J Exp Clin Cancer Res Research BACKGROUND: Breast cancer is a highly heterogeneous pathology, exhibiting a number of subtypes commonly associated with a poor outcome. Due to their high stability, microRNAs are often regarded as non-invasive cancer biomarkers, having an expression pattern specific for their ‘cell of origin’. METHOD: Triple negative breast cancer (TNBC: ER-, PR-, Her-2-) and double positive breast cancer (DPBC: ER+, PR+, Her-2) miRNA expression patterns were obtained by analysis of the TCGA (The Cancer Genome Atlas) data, followed by PCR-array analysis on plasma samples from 20 TNBC patients, 14 DPBC patients and 11 controls. RESULTS: Three downregulated and nine upregulated miRNAs were obtained from the TNBC analysis. Five overexpressed miRNAs were identified in the DPBC group. Four of the dysregulated miRNAs (miR-10a, miR-125b, miR-210 and miR-489) were common for both groups. The cluster miR-17-92 (miR-17, miR-20a, miR-20b, and miR-93), along with miR-130, miR-22 and miR-29a/c, were found to differentiate between TNBC and DPBC. A panel of five transcripts (miR-10a, miR-125, miR-193b, miR-200b and miR-489) was validated in a new set of plasma samples. The overlapping of TCGA and plasma profiling data revealed miR-200b, miR-200c, miR-210 and miR-29c as common signature. MiR-200b was validated on additional normal and tumor tissue samples. The expression level of this transcript from the TCGA data was correlated with lung and bone metastatic genes. CONCLUSION: The miR-200b presents a great potential for the future advancements in the diagnostic/prognostic and therapeutic approach of TNBC, along with other coding or non-coding transcripts. However, this needs to be further integrated in a regulatory network that acts in conjunction with other markers that affect the patients’ prognosis or response to therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13046-018-0920-2) contains supplementary material, which is available to authorized users. BioMed Central 2018-10-20 /pmc/articles/PMC6196003/ /pubmed/30342533 http://dx.doi.org/10.1186/s13046-018-0920-2 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Braicu, Cornelia
Raduly, Lajos
Morar-Bolba, Gabriela
Cojocneanu, Roxana
Jurj, Ancuta
Pop, Laura-Ancuta
Pileczki, Valentina
Ciocan, Cristina
Moldovan, Alin
Irimie, Alexandru
Eniu, Alexandru
Achimas-Cadariu, Patriciu
Paradiso, Angelo
Berindan-Neagoe, Ioana
Aberrant miRNAs expressed in HER-2 negative breast cancers patient
title Aberrant miRNAs expressed in HER-2 negative breast cancers patient
title_full Aberrant miRNAs expressed in HER-2 negative breast cancers patient
title_fullStr Aberrant miRNAs expressed in HER-2 negative breast cancers patient
title_full_unstemmed Aberrant miRNAs expressed in HER-2 negative breast cancers patient
title_short Aberrant miRNAs expressed in HER-2 negative breast cancers patient
title_sort aberrant mirnas expressed in her-2 negative breast cancers patient
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196003/
https://www.ncbi.nlm.nih.gov/pubmed/30342533
http://dx.doi.org/10.1186/s13046-018-0920-2
work_keys_str_mv AT braicucornelia aberrantmirnasexpressedinher2negativebreastcancerspatient
AT radulylajos aberrantmirnasexpressedinher2negativebreastcancerspatient
AT morarbolbagabriela aberrantmirnasexpressedinher2negativebreastcancerspatient
AT cojocneanuroxana aberrantmirnasexpressedinher2negativebreastcancerspatient
AT jurjancuta aberrantmirnasexpressedinher2negativebreastcancerspatient
AT poplauraancuta aberrantmirnasexpressedinher2negativebreastcancerspatient
AT pileczkivalentina aberrantmirnasexpressedinher2negativebreastcancerspatient
AT ciocancristina aberrantmirnasexpressedinher2negativebreastcancerspatient
AT moldovanalin aberrantmirnasexpressedinher2negativebreastcancerspatient
AT irimiealexandru aberrantmirnasexpressedinher2negativebreastcancerspatient
AT eniualexandru aberrantmirnasexpressedinher2negativebreastcancerspatient
AT achimascadariupatriciu aberrantmirnasexpressedinher2negativebreastcancerspatient
AT paradisoangelo aberrantmirnasexpressedinher2negativebreastcancerspatient
AT berindanneagoeioana aberrantmirnasexpressedinher2negativebreastcancerspatient